Want to see AU:MVF full AI Analyst Report?
MVF Stock Chart & Stats
AU$0.76
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.76
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.58 - AU$0.90
Previous CloseN/A
Volume300.99K
Average Volume (3M)2.18M
Market Cap
AU$263.00M
Enterprise ValueAU$481.35
Total Cash (Recent Filing)AU$8.14M
Total Debt (Recent Filing)AU$281.81M
Price to Earnings (P/E)17.7
Beta1.23
Next Earnings
Aug 24, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend Yield5.49%
Share Statistics
EPS (TTM)0.04
Shares Outstanding389,634,830
10 Day Avg. Volume1,374,502
30 Day Avg. Volume2,181,726
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.12
Price to Sales (P/S)1.01
P/FCF Ratio588.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.79Price Target Upside3.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$277.25M
Bulls Say, Bears Say
Bulls Say
Clinic Network & Specialist ServicesA nationwide clinic and laboratory network with specialist medical and embryology staff establishes a durable service platform. Recurring treatment cycles and specialist delivery create high customer touch, operational scale and barriers to entry that support steady long-term revenue generation.
Strong Recent Revenue And Profit MarginsA large recent revenue uplift combined with healthy gross (33.2%) and net (9.2%) margins implies the business can convert demand into sustainable profitability. Durable margins across a clinical services model support reinvestment in clinics, labs and talent for multi‑period growth.
Moderate Leverage And Solid ROEA balanced capital structure (D/E ~0.73) with a mid‑teens ROE indicates prudent use of leverage and efficient equity deployment. This provides the firm financial flexibility to fund expansion, maintain clinic operations and support dividends without excessive refinancing risk.
Bears Say
Collapse In Free Cash FlowA near-total decline in free cash flow and low OCF-to-net-income conversion (0.21) materially reduces internal funding capacity. Over months this constrains capex, clinic investment, dividend sustainability and increases reliance on external financing, weakening long-run financial resilience.
Margin And EBITDA VolatilityReported volatility in operating margins signals sensitivity to cost structure, treatment mix or pricing dynamics. For a service business, unstable EBIT/EBITDA undermines cash predictability and makes multi‑period planning, pricing strategy and capital allocation riskier for sustained profitability.
Recent Reported Revenue Growth InconsistencyA negative recent revenue growth metric despite prior spikes suggests inconsistency in demand or lapping effects. Over a 2–6 month horizon this raises questions about capacity utilization, pricing sustainability and the ability to maintain the elevated revenue base without recurring volume recovery.
Monash IVF Group Ltd News
MVF FAQ
What was Monash IVF Group Ltd’s price range in the past 12 months?
Monash IVF Group Ltd lowest share price was AU$0.57 and its highest was AU$0.90 in the past 12 months.
What is Monash IVF Group Ltd’s market cap?
Monash IVF Group Ltd’s market cap is AU$263.00M.
When is Monash IVF Group Ltd’s upcoming earnings report date?
Monash IVF Group Ltd’s upcoming earnings report date is Aug 24, 2026 which is in 33 days.
How were Monash IVF Group Ltd’s earnings last quarter?
Monash IVF Group Ltd released its earnings results on Feb 25, 2026. The company reported AU$0.018 earnings per share for the quarter, missing the consensus estimate of AU$0.025 by -AU$0.007.
Is Monash IVF Group Ltd overvalued?
According to Wall Street analysts Monash IVF Group Ltd’s price is currently Undervalued.
Does Monash IVF Group Ltd pay dividends?
Monash IVF Group Ltd pays a Semiannually dividend of AU$0.012 which represents an annual dividend yield of 5.49%. See more information on Monash IVF Group Ltd dividends here
What is Monash IVF Group Ltd’s EPS estimate?
Monash IVF Group Ltd’s EPS estimate is 0.02.
How many shares outstanding does Monash IVF Group Ltd have?
Monash IVF Group Ltd has 389,634,830 shares outstanding.
What happened to Monash IVF Group Ltd’s price movement after its last earnings report?
Monash IVF Group Ltd reported an EPS of AU$0.018 in its last earnings report, missing expectations of AU$0.025. Following the earnings report the stock price went up 2.954%.
Which hedge fund is a major shareholder of Monash IVF Group Ltd?
Currently, no hedge funds are holding shares in AU:MVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monash IVF Group Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.79 (3.42% Upside)
AU$0.79 (3.42% Upside)
Blogger Sentiment
Bullish
AU:MVF Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.39%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
0.49%
Trailing 12-Months
Company Description
Monash IVF Group Ltd
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This includes diagnostic obstetric and gynecological ultrasound examinations, a range of fertility treatments, and advanced tertiary-level prenatal diagnostics. The company is also a key provider of in-vitro fertilization (IVF) services.
MVF Stock 12 Month Forecast
Average Price Target
AU$0.79
▲(3.42% Upside)
Technical Analysis
Genetic Technologies
―
Healius Limited
―
Cryosite Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―






